Compare AstraZeneca plc (AZN) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Petróleo Brasileiro SA — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Petróleo Brasileiro SA trades at $17.8 (market cap $112.19B). The key difference: AstraZeneca plc is far larger — about 2.2× Petróleo Brasileiro SA's market cap, and Petróleo Brasileiro SA pays the higher dividend (9.42%). Which is the better fit depends on your goals.
| AZN | PBR | |
|---|---|---|
Market Cap | $248.14B | $112.19B |
Sector | Health | Technology |
52-Week High | $209.48 | $22.03 |
52-Week Low | $147.06 | $11.54 |
Enterprise Value | $275.41B | $172.61B |
Dividend Yield | 2.01% | 9.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Petrobras (PBR) trades at $17.76, down 3.11% today, amid bearish technical signals despite strong Q2 2026 results showing record production and earnings growth. The company maintains robust fundamentals with a P/E of 4.53, ROE of 30.77%, and consistent dividend payments, though cash flow turned negative in 2026. Recent news highlights production exceeding forecasts and strategic expansions in deepwater operations.
PBR presents a value opportunity with attractive valuations and high profitability, but faces headwinds from regulatory uncertainty and volatile oil prices. Analyst consensus is bullish (50% Buy ratings), yet technical indicators suggest near-term pressure. Investors should weigh strong fundamentals against geopolitical and operational risks in the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
